Skip to main content
. 2018 Jan 16;17(3):4229–4236. doi: 10.3892/mmr.2018.8437

Figure 3.

Figure 3.

MDM2 is a downstream target of miR-188-3p. (A) Candidate targets of miR-188-3p were predicted using miRNA and TargetScan databases. MDM2 was selected as a putative target of miR-188-3p. (B) SH-SY5Y neuroblastoma cells were co-transfected with a luciferase vector containing a wild-type or mutant version of the MDM2 3′UTR and NC miRNA or miR-188-3p mimics, and the luciferase activity was measured. The expression level of miR-188-3p was detected by RT-qPCR as shown in left panel. (C) mRNA expression of MDM2 was detected in the hippocampal tissues of rats that were treated with miR-188-3p mimics or miR-188-3p inhibitor after sevoflurane administration, n=8/group. (D) Protein expression of MDM2 in the hippocampal tissues of rats transduced with miR-188-3p mimics, miR-188-3p inhibitor and the respective controls was determined by western blot analysis. GAPDH was used as the loading control, n=8/group. (E) mRNA and (F) protein levels of MDM2 in the hippocampal tissues of rats with or without sevoflurane treatment were detected by reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively, n=8/group. **P<0.01 and ***P<0.001 as indicated. MDM2, MDM2 proto-oncogene; miR/miRNA, microRNA; UTR, untranslated region; NC, negative control; ns, not significant.